210 related articles for article (PubMed ID: 10908291)
1. Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues.
Palmer D; Maurice DH
Mol Pharmacol; 2000 Aug; 58(2):247-52. PubMed ID: 10908291
[TBL] [Abstract][Full Text] [Related]
2. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP.
Liu H; Maurice DH
Br J Pharmacol; 1998 Dec; 125(7):1501-10. PubMed ID: 9884079
[TBL] [Abstract][Full Text] [Related]
3. Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo.
Tilley DG; Maurice DH
Mol Pharmacol; 2002 Sep; 62(3):497-506. PubMed ID: 12181425
[TBL] [Abstract][Full Text] [Related]
4. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice.
Sun B; Li H; Shakur Y; Hensley J; Hockman S; Kambayashi J; Manganiello VC; Liu Y
Cell Signal; 2007 Aug; 19(8):1765-71. PubMed ID: 17482796
[TBL] [Abstract][Full Text] [Related]
5. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium.
Hambleton R; Krall J; Tikishvili E; Honeggar M; Ahmad F; Manganiello VC; Movsesian MA
J Biol Chem; 2005 Nov; 280(47):39168-74. PubMed ID: 16172121
[TBL] [Abstract][Full Text] [Related]
6. Differential cellular pattern of gene expression for two distinct cGMP-inhibited cyclic nucleotide phosphodiesterases in developing and mature rat brain.
Reinhardt RR; Bondy CA
Neuroscience; 1996 May; 72(2):567-78. PubMed ID: 8737425
[TBL] [Abstract][Full Text] [Related]
7. Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease.
Netherton SJ; Jimmo SL; Palmer D; Tilley DG; Dunkerley HA; Raymond DR; Russell JC; Absher PM; Sage EH; Vernon RB; Maurice DH
Diabetes; 2002 Apr; 51(4):1194-200. PubMed ID: 11916944
[TBL] [Abstract][Full Text] [Related]
8. Reduced phosphodiesterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells: implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues.
Dunkerley HA; Tilley DG; Palmer D; Liu H; Jimmo SL; Maurice DH
Mol Pharmacol; 2002 May; 61(5):1033-40. PubMed ID: 11961121
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.
Murray F; MacLean MR; Pyne NJ
Br J Pharmacol; 2002 Dec; 137(8):1187-94. PubMed ID: 12466227
[TBL] [Abstract][Full Text] [Related]
10. Cyclic nucleotide phosphodiesterase 3 expression in vivo: evidence for tissue-specific expression of phosphodiesterase 3A or 3B mRNA and activity in the aorta and adipose tissue of atherosclerosis-prone insulin-resistant rats.
Nagaoka T; Shirakawa T; Balon TW; Russell JC; Fujita-Yamaguchi Y
Diabetes; 1998 Jul; 47(7):1135-44. PubMed ID: 9648839
[TBL] [Abstract][Full Text] [Related]
11. Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3).
He R; Komas N; Ekholm D; Murata T; Taira M; Hockman S; Degerman E; Manganiello VC
Cell Biochem Biophys; 1998; 29(1-2):89-111. PubMed ID: 9631240
[TBL] [Abstract][Full Text] [Related]
12. Cyclic AMP phosphodiesterases in human lymphocytes.
Sheth SB; Chaganti K; Bastepe M; Ajuria J; Brennan K; Biradavolu R; Colman RW
Br J Haematol; 1997 Dec; 99(4):784-9. PubMed ID: 9432022
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 3B (PDE3B) antagonizes the anti-angiogenic actions of PKA in human and murine endothelial cells.
MacKeil JL; Brzezinska P; Burke-Kleinman J; Theilmann AL; Nicol CJB; Ormiston ML; Maurice DH
Cell Signal; 2019 Oct; 62():109342. PubMed ID: 31176020
[TBL] [Abstract][Full Text] [Related]
14. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors.
Palmer D; Tsoi K; Maurice DH
Circ Res; 1998 May; 82(8):852-61. PubMed ID: 9576105
[TBL] [Abstract][Full Text] [Related]
15. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.
Verghese MW; McConnell RT; Lenhard JM; Hamacher L; Jin SL
Mol Pharmacol; 1995 Jun; 47(6):1164-71. PubMed ID: 7603456
[TBL] [Abstract][Full Text] [Related]
16. New insight into the role of phosphodiesterase 3A in porcine oocyte maturation.
Sasseville M; Côté N; Guillemette C; Richard FJ
BMC Dev Biol; 2006 Oct; 6():47. PubMed ID: 17038172
[TBL] [Abstract][Full Text] [Related]
17. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
18. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
Rose RJ; Liu H; Palmer D; Maurice DH
Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase 3A expression and activity in the murine vasculature is influenced by NO-sensitive guanylyl cyclase.
Dünnes S; Voussen B; Aue A; Groneberg K; Nikolaev V; Groneberg D; Friebe A
Pflugers Arch; 2018 Apr; 470(4):693-702. PubMed ID: 29294149
[TBL] [Abstract][Full Text] [Related]
20. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.
Zhang W; Ke H; Tretiakova AP; Jameson B; Colman RW
Protein Sci; 2001 Aug; 10(8):1481-9. PubMed ID: 11468344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
